The estimated Net Worth of Craig R. Rayner is at least $8.25 Milion dollars as of 2 September 2021. Craig Rayner owns over 54,462 units of Certara stock worth over $3,469,790 and over the last 4 years Craig sold CERT stock worth over $4,779,041.
Craig has made over 2 trades of the Certara stock since 2021, according to the Form 4 filled with the SEC. Most recently Craig sold 54,462 units of CERT stock worth $1,978,604 on 2 September 2021.
The largest trade Craig's ever made was selling 108,924 units of Certara stock on 11 June 2021 worth over $2,800,436. On average, Craig trades about 54,462 units every 28 days since 2021. As of 2 September 2021 Craig still owns at least 316,010 units of Certara stock.
You can see the complete history of Craig Rayner stock trades at the bottom of the page.
Craig's mailing address filed with the SEC is C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON, NJ, 08540.
Over the last 5 years, insiders at Certara have traded over $2,048,278,243 worth of Certara stock and bought 97,245 units worth $1,908,085 . The most active insiders traders include Avatar Parent L.P.Eqt Avata..., James E Iii Cashman oraz Mason P Slaine. On average, Certara executives and independent directors trade stock every 14 days with the average trade being worth of $7,828,136. The most recent stock trade was executed by Leif E Pedersen on 9 September 2024, trading 51,224 units of CERT stock currently worth $578,319.
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Certara executives and other stock owners filed with the SEC include: